The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1193-1202

  Stutterheim, J ^a,b   Zappeij Kannegieter, L ^b   Versteeg, R ^b   Caron, H N ^a   Van Der Schoot, C E ^b,c   Tytgat, G A M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Bone marrow; Minimal residual disease (MRD); Neuroblastoma; PHOX2B; Prognosis; Quantitative real time polymerase chain reaction (qPCR); Tyrosine hydroxylase

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CARBOPLATIN; CHOLINERGIC RECEPTOR 3; DOPAMINE DECARBOHYDROXYLASE; ETOPOSIDE; IFOSFAMIDE; NEUROMODULIN; PAIRED LIKE HOMEOBOX2B; TUMOR MARKER; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BONE MARROW DISEASE; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

EID: 79955534573     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.003     Document Type: Article

References (23)

1. K.K. Matthay, J.G. Villablanca, and R.C. Seeger Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N Engl J Med 341 1999 1165 1173 (Pubitemid 29480654)
2. J. Stutterheim, A. Gerritsen, and L. Zappeij-Kannegieter PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma J Clin Oncol 26 2008 5443 5449
3. V.F. Viprey, M.V. Corrias, and B. Kagedal Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET Eur J Cancer 43 2007 341 350 (Pubitemid 46123979)
4. G.M. Brodeur, J. Pritchard, and F. Berthold Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 11 1993 1466 1477 (Pubitemid 23228250)
5. R.C. Seeger, C.P. Reynolds, and R. Gallego Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study J Clin Oncol 18 2000 4067 4076 (Pubitemid 32038399)
6. I.Y. Cheung, M.S. Lo Piccolo, and B.H. Kushner Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma J Clin Oncol 21 2003 3853 3858 (Pubitemid 46606241)
7. M. Fukuda, Y. Miyajima, and Y. Miyashita Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study J Pediatr Hematol Oncol 23 2001 10 13 (Pubitemid 32124978)
8. A. Tchirkov, C. Paillard, and P. Halle Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma J Hematother Stem Cell Res 12 2003 435 442 (Pubitemid 36993431)
9. J. Stutterheim, A. Gerritsen, and L. Zappeij-Kannegieter Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers Clin Chem 55 2009 1316 1326
10. J. de Kraker, K.A. Hoefnagel, and A.C. Verschuur Iodine-131- metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age Eur J Cancer 44 2008 551 556
11. A.D. Pearson, C.R. Pinkerton, and I.J. Lewis High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial Lancet Oncol 9 2008 247 256 (Pubitemid 351722944)
12. F. Berthold, J. Boos, and S. Burdach Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial Lancet Oncol 6 2005 649 658 (Pubitemid 41222755)
13. E. Beillard, N. Pallisgaard, and V. van der Velden Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program Leukemia 17 2003 2474 2486 (Pubitemid 38072587)
14. T. Szczepanski, A. Orfao, and V. van der Velden Minimal residual disease in leukaemia patients Lancet Oncol 2 2001 409 417 (Pubitemid 33585945)
15. K. Beiske, S.A. Burchill, and I.Y. Cheung Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force Br J Cancer 100 2009 1627 1637
16. I.Y. Cheung, M.S. Lo Piccolo, and B.H. Kushner Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma J Clin Oncol 21 2003 1087 1093 (Pubitemid 46594138)
17. S.A. Burchill, I.J. Lewis, and K.R. Abrams Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year J Clin Oncol 19 2001 1795 1801 (Pubitemid 32230882)
18. A. Parareda, S. Gallego, and J. Roma Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma Oncol Rep 14 2005 1021 1027
19. M.V. Corrias, L.B. Faulkner, and A. Pistorio Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients Clin Cancer Res 10 2004 7978 7985 (Pubitemid 39587539)
20. V.F. Viprey, M.A. Lastowska, and M.V. Corrias Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials J Pathol 216 2008 245 252
21. C. Trager, A. Vernby, and A. Kullman MRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis Int J Cancer 123 2008 2849 2855
22. A. Oberthuer, J. Theissen, and F. Westermann Molecular characterization and classification of neuroblastoma Future Oncol 5 2009 625 639
23. I.Y. Cheung, Y. Feng, and W. Gerald Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma Clin Cancer Res 14 2008 7020 7027